L
Laurence Chu
Publications - 15
Citations - 332
Laurence Chu is an academic researcher. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 8, co-authored 9 publications receiving 210 citations.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study
D. Gray Heppner,Tracy Kemp,Brian K. Martin,William Jay Ramsey,Richard A. Nichols,Emily J Dasen,Charles J. Link,Rituparna Das,Zhi Jin Xu,Eric A Sheldon,Teresa Nowak,Thomas P. Monath,Donald Gray Heppner,TL Kemp,Brian K. Martin,WJ Ramsey,Rick Nichols,EJ Dasen,Joan Fusco,Joseph D. Crowell,Charles J. Link,J Creager,Thomas P. Monath,R Das,ZJ Xu,R Klein,Tomasz Nowak,Eric Gerstenberger,R Bliss,EA Sheldon,RA Feldman,Brandon Essink,WB Smith,Laurence Chu,WM Seger,J Saleh,JL Borders,M Adams +37 more
TL;DR: The safety and immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSV∆G-ZEBOV-GP) is reported across a 6 log10 dose range in two sequential cohorts.
Journal ArticleDOI
Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
Scott A. Halperin,Jose R. Arribas,Richard E. Rupp,Charles P. Andrews,Laurence Chu,Rituparna Das,Jakub K. Simon,Matthew T. Onorato,Kenneth Liu,Jason C. Martin,Frans A. Helmond +10 more
TL;DR: The safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP) was evaluated in this paper.
Journal ArticleDOI
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
Laurence Chu,Keith Vrbicky,David C. Montefiori,Wenmei Huang,Biliana Nestorova,Ying Chang,Andrea Carfi,Darin K. Edwards,Judith L. Oestreicher,Holly M. Legault,Frank J. Dutko,B. Girard,Rolando Pajon,Jacqueline M. Miller,R. Das,Brett Leav,Roderick McPhee +16 more
TL;DR: The results of the open-label, non-randomized part B of a phase 2 trial in which they evaluated the safety and immunogenicity of a booster injection of 50 µg of the coronavirus disease 2019 (COVID-19) vaccine mRNA-1273 in 344 adult participants immunized 6-8 months earlier with a primary two-dose series with a vaccine as discussed by the authors .
Journal ArticleDOI
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
Jiři Beran,Jason D Lickliter,Tino F. Schwarz,Casey P. Johnson,Laurence Chu,Joseph B. Domachowske,Pierre Van Damme,Kanchanamala Withanage,Laurence Fissette,Marie-Pierre David,Koen Maleux,Alexander Schmidt,Marta Picciolato,Ilse Dieussaert +13 more
TL;DR: The investigational vaccine was well tolerated and had a safety profile similar to that of the widely used combined Tdap vaccine.
Journal ArticleDOI
Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial
Varsha K. Jain,Joseph B. Domachowske,Long Wang,Opokua Ofori-Anyinam,Miguel Angel Rodríguez-Weber,Michael Leonardi,Nicola P. Klein,Gary Schlichter,Robert Jeanfreau,Byron L. Haney,Laurence Chu,Jo Ann S. Harris,Kwabena O. Sarpong,Amanda C. Micucio,Jyoti Soni,Vijayalakshmi Chandrasekaran,Ping Li,Bruce L. Innis +17 more
TL;DR: Double-dose IIV4 may improve protection against influenza B in some young children and simplifies annual influenza vaccination by allowing the same vaccine dose to be used for all eligible children and adults.